MetaCap

Polyrizon (PLRZ) vs TELA Bio (TELA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Polyrizon (PLRZ) has outperformed TELA Bio (TELA) over the past year, gaining 144.0% versus a loss of 41.2%. TELA Bio is the larger company by market cap ($31.1 million vs $22.6 million), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLRZ+143.97%TELA-41.15%
+370%+149%-72%
Nov 21, 20251 yearNov 20, 2026
PLRZ-99.47%TELA-76.26%
+74%-17%-108%
Oct 28, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLRZ versus TELA key metrics
MetricPLRZTELA
Share price$9.31$0.6885
Market cap$22.61M$31.11M
1-day change-8.42%-5.27%
YTD return+9.66%-41.65%
1-year return+143.97%-41.15%
5-year return—-94.37%
EPS (TTM)$-4.97$-0.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$80.28M
Revenue growth (YoY)—+15.84%
Net income (latest FY)$-3.33M$-38.83M
Gross margin—67.69%
Operating margin—-42.05%
Net margin—-48.37%
52-week high$18.20$1.50
52-week low$2.88$0.501
Distance from 52-week high-48.85%-54.10%
Analyst consensus—strong_buy
Avg. price target upside—+202.11%
Average volume38.21K217.44K
Shares outstanding2.43M45.19M
Employees2218
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLRZ has outperformed TELA by 185.1 percentage points over the past year.

About Polyrizon

PLRZ stock →

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.

Health Care · Medical/Dental Instruments · 2 employees

About TELA Bio

TELA stock →

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Health Care · Medical/Dental Instruments · 218 employees

PLRZ vs TELA FAQ

Which is bigger, Polyrizon or TELA Bio?

TELA Bio (TELA) is larger, with a market capitalization of $31.11M compared with $22.61M for Polyrizon (PLRZ).

Which stock has performed better over the past year, PLRZ or TELA?

PLRZ returned +143.97% over the past 12 months, compared with -41.15% for TELA (price return, excluding dividends). Past performance does not predict future results.

Are Polyrizon and TELA Bio in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons